Allergy Therapeutics (AGY)

 

Allergy Therapeutics vaccine gains CTA spproval

Allergy Therapeutics has received approval for a clinical study of its novel house dust mite allergy vaccine.

The company said a phase I clinical study investigating the safety and tolerability of Acarovac MPL (monophosphoryl lipid A) had received clinical trial application (CTA) approval in Spain.

The company said: "House dust mites are a major cause of perennial allergic rhinitis and allergic asthma.

"Acarovac MPL builds on the strong foundation of technologies employed in the successful Pollinex Quattro range of subcutaneous allergy immunotherapies, and builds on the demonstrated efficacy of the existing successful product platform of Acarovac Plus, the fastest growing 'named-patient product' in Allergy Therapeutics' Spanish subsidiary.

"Acarovac MPL is the only house-dust mite immunotherapy in development utilising MCT (microcrystalline tyrosine), a natural, biodegradable depot, and the adjuvant MPL for the treatment of perennial allergic rhinitis making this vaccine unique in a $1.5bn per annum market."